MENLO PARK, Calif., Sept. 15 /PRNewswire/ _- Perclose, Inc. (Nasdaq: PERC)
today announced that its board of directors has authorized the repurchase of
up to 500,000 shares of its outstanding common shares, effective immediately.
The company may repurchase the shares in the open market or in privately
negotiated transactions, from time to time, subject to market conditions.  The
number of shares of common stock actually acquired by Perclose will depend on
several factors, and the repurchase program may be interrupted or discontinued
at any time.  The company currently has approximately 10.8 million shares
outstanding.
    "This share repurchase program clearly demonstrates the board of
directors' and management's confidence in Perclose's long-term prospects and
is consistent with the company's continuing efforts to enhance shareholder
value," said Hank Plain, president and chief executive officer.
    Perclose, based in Menlo Park, Calif., designs, manufactures and markets
less invasive medical devices that automate the surgical closure or connection
of blood vessels.  The Prostar(R) and Techstar(R) products, marketed in the
U.S. and internationally, surgically close the arterial access site in the
femoral artery following catheterization procedures such as angioplasty,
stenting, atherectomy and diagnostic angiography.  The patented, proprietary
Prostar and Techstar products offer superior clinical treatment, more rapid
recovery and a more cost-effective alternative to the standard method of
closing arterial access sites.  The Heartflo(TM) System, which automates the
surgical connection of blood vessels during conventional and minimally
invasive coronary artery bypass surgery, is in human clinical testing.
Perclose common stock is traded on the Nasdaq National Market under the symbol
PERC.
    Except for the historical information contained herein, the matters
discussed in this news release are forward looking statements that involve
risk and uncertainties, including the risk that new products may not prove to
be safe or effective in clinical trials, risks associated with receipt and
timing of regulatory approvals, including approvals to conduct clinical trials
and to commercially market products, market acceptance of new products, risks
of adverse determinations in litigation relating to patents and intellectual
property rights, risks associated with manufacturing scale-up and increases in
production volumes, risks associated with product recalls and the management
of growth.  For further information, refer to the risk factors in the most
recent periodic filings with the Securities and Exchange Commission.

Link to this page: